Taiwan sets up major new biotech fund
This article was originally published in Scrip
Taiwan is to set up a NT$60 billion ($1.8 billion) venture capital fund to support the development of its biotech industry. The move aims to double the total output value of the sector to NT$260 billion by 2012, raising it to NT$1,000 billion within 10 years.
You may also be interested in...
First-line lung cancer approval will expand potential market for Takeda's ALK contender but the latecomer is also facing some well-established class competition in the setting.
US venture raises new funds from Asia partners as it builds a direct presence in China to develop its oncology portfolio.
Novartis gene therapy gets insurance coverage at record price although small patient population will limit system costs.